COTA becomes newest member of the Clinical Research Data Sharing Alliance to advance clinical trial and real-world data in oncology

COTA is joining the Clinical Research Data Sharing Alliance to explore the complementary use of real-world and clinical trial data in research and drug development.

COTA Inc has announced they have been invited to form a strategic partnership with the Clinical Research Data Sharing Alliance (CRDSA) to explore new opportunities to advance the discovery of new treatments through clinical trials and real-world data (RWD). An oncology RWD and analytics company, COTA will join other CRDSA member organizations to participate in the Alliance’s steering committee and the Innovative Trial Design Working Group, who are focusing on non-small cell lung cancer. As well as researching ways to leverage RWD and clinical trial data in drug development, COTA will also help the alliance develop support and guidance to create best practices and guidelines for using these diverse data types in regulatory decision making and other uses.

Founded in 2021, CRDSA is nonprofit, multi-stakeholder association including biopharma companies, data sharing platforms, academic institutions, and service and technology partners. COTA was chosen to join the alliance due to their shared vision that widespread access to de-identified patient data has the potential to transform research and clinical trials, leading to improved drug development and better outcomes for patients.

“Responsible, ethical, and compliant data sharing has the potential to revolutionize healthcare. However, we are still in the early stages when it comes to data standardization, regulatory guidance, and governing policies,” explained C.K. Wang, M.D., Chief Medical Officer at COTA. “We are pleased to work with cross-industry groups like CRDSA as they build trust and demonstrate the value of data sharing for all stakeholder groups, particularly patients.”

Since 2011, COTA has been committed to creating a precise, patient-first approach to cancer care through the use of RWD. The company provides advanced analytics of oncology RWD from leading academic and community-based cancer centers, including U.S. Food and Drug Administration, Friends of Cancer Research, University of Chicago Medicine, UT Southwestern Medical Center and University of Rochester, to help cross-industry stakeholders advance cancer care and treatment.